COPD Beyond Inhalers

COPD Beyond Inhalers

Can biologics reach more patients?

IL-33 inhibition may extend exacerbation prevention beyond eosinophil-selected trials, but important questions remain.

WHY LOOK BEYOND INHALERS?

Moderate or severe exacerbations persist in some patients despite optimized maintenance inhaled therapy. Biologics are being studied as add-on prevention for selected patients.

TARGETING IL-33

Tozorakimab is an investigational antibody against interleukin-33. OBERON and TITANIA did not require a blood-eosinophil threshold for enrollment.

Two replicate phase 3 trials

Former smokers | Primary endpoint | 52 weeks

WHAT THE FINDINGS MEAN

Both trials found fewer moderate or severe exacerbations in former smokers, with statistically significant results also in the overall current/former-smoker populations. This does not establish equal benefit across eosinophil subgroups or improved survival.

THE MEDEASY TAKE

Broader eligibility for study is not proof of benefit for every COPD phenotype. Efficacy, safety, and patient selection still matter.

Different Targets. Different Evidence.

Why COPD biologic trials cannot be ranked by headline percentages.

01 DUPILUMAB RR 0.70 / 0.66

IL-4 / IL-13 | BOREAS + NOTUS

Blood eosinophils ≥300 cells/µL, chronic bronchitis, and exacerbation risk despite optimized inhaled treatment.

Fewer exacerbations and improved FEV1 versus placebo.

95% CIs: 0.58–0.86 (BOREAS); 0.54–0.82 (NOTUS).

02 MEPOLIZUMAB RR 0.79

IL-5 | MATINEE

Blood eosinophils ≥300 cells/µL and prior exacerbations despite triple inhaled therapy.

0.80 vs 1.01 events/year; no significant QoL or symptom difference.

95% CI: 0.66–0.94 (MATINEE).

03 TOZORAKIMAB RR 0.71 / 0.66

IL-33 | OBERON + TITANIA

Former smokers were the primary-analysis populations; no minimum eosinophil count was required for enrollment.

Fewer exacerbations vs placebo; subgroup equivalence is unproven. Investigational therapy.

95% CIs: 0.57–0.88 (OBERON); 0.55–0.80 (TITANIA).

WHY THE NUMBERS CANNOT BE RANKED

Different entry criteria, inflammatory phenotypes, background treatment and smoking status limit cross-trial comparisons. These are separate placebo-controlled trials, not head-to-head evidence.

MEDEASY TAKE Match proven outcomes to the patient—not the headline rate ratio.

COPD Biologics: Who Is the Right Patient?

From trial eligibility to careful clinical adoption.

01 OPTIMIZE BEFORE ESCALATING

Confirm COPD with spirometry; review exacerbation history, inhaler technique, adherence, and appropriate maintenance therapy. Address smoking, vaccination, pulmonary rehabilitation, and comorbidities.

Clinical pearl: Recurrent exacerbations—not dyspnea alone—drive biologic assessment.

02 MATCH THE PATIENT TO THE EVIDENCE

DUPILUMAB

Eosinophils ≥300 cells/µL, chronic bronchitis, and exacerbations despite triple therapy.

MEPOLIZUMAB

Eosinophils ≥300 cells/µL and exacerbations despite triple therapy; chronic bronchitis not mandatory.

TOZORAKIMAB

Investigational IL-33 blocker; no minimum eosinophil count at enrollment. Benefit across all phenotypes is unproven.

03 REASSESS SAFETY & PATIENT-RELEVANT BENEFIT

Review agent-specific warnings and adverse effects; monitor exacerbations, function, and tolerability. There is no universal 4–6-month stopping rule. Reassess continuation according to response, safety, and specialist guidance.

04 PROSPERO: LONGER-TERM EVIDENCE RR 0.79 95% CI 0.61–1.01 | P=0.0587

At up to 104 weeks, the former-smoker primary endpoint (severe COPD exacerbations) was not statistically significant. An overall-population result was nominally significant; it is not confirmatory after a missed primary endpoint. CHEST 2026 · Sponsor-reported conference results; preliminary.

PHILIPPINE PRACTICE CHECK

Check Philippine FDA indication, access, cost, and follow-up. Global approval does not establish local approval.

THE MEDEASY TAKE

Select patients by exacerbation history and trial criteria. Prioritize safety and outcomes, not headline percentages.